Analyst Activity – BMO Capital Markets Lowers Its Price Target On Biogen (NASDAQ:BIIB) to $284.70

ME Staff
-
0

Analyst Ratings For Biogen (NASDAQ:BIIB)

Today, BMO Capital Markets lowered its price target on Biogen (NASDAQ:BIIB) to $284.70 per share.

There are 11 hold ratings, 13 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Biogen (NASDAQ:BIIB) is Buy (Score: 2.60) with a consensus target price of $329.26 per share, a potential 11.38% upside.

Some recent analyst ratings include

  • 7/26/2017-Morgan Stanley Reiterated Rating of Equal Weight.
  • 7/26/2017-Deutsche Bank AG Reiterated Rating of Buy.
  • 7/26/2017-Leerink Swann Reiterated Rating of Market Perform.
  • 7/26/2017-Goldman Sachs Group, Inc. (The) Upgrade from a “Neutral ” rating to a ” Buy” rating.
  • 7/11/2017-Jefferies Group LLC Reiterated Rating of Hold .

Recent Insider Trading Activity For Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) has insider ownership of 0.32% and institutional ownership of 87.50%.

  • On 7/19/2017 Susan H Alexander, EVP, sold 7,758 with an average share price of $285.00 per share and the total transaction amounting to $2,211,030.00. View SEC Filing
  • On 6/9/2017 Brian S Posner, Director, sold 1,084 with an average share price of $256.31 per share and the total transaction amounting to $277,840.04. View SEC Filing
  • On 5/1/2017 Michel Vounatsos, CEO, bought 1,402 with an average share price of $271.35 per share and the total transaction amounting to $380,432.70. View SEC Filing
  • On 4/27/2017 Alexander J. Denner, Director, bought 73,858 with an average share price of $278.50 per share and the total transaction amounting to $20,569,453.00. View SEC Filing
  • On 4/25/2017 Paul J Clancy, VP, sold 9,892 with an average share price of $290.00 per share and the total transaction amounting to $2,868,680.00. View SEC Filing
  • On 4/3/2017 Alfred Sandrock, CMO, sold 1,981 with an average share price of $274.08 per share and the total transaction amounting to $542,952.48. View SEC Filing
  • On 3/13/2017 Paul J Clancy, VP, sold 9,891 with an average share price of $291.55 per share and the total transaction amounting to $2,883,721.05. View SEC Filing

Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at 295.61 up +12.65 4.47% with 3,110,019 shares trading hands.